Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 10, 2024Blood AdvancesOpen Access

An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL

View Full Paper
Ask AI
Bookmark
Share

Authors

AKAdam S. KittaiThe Ohio State University Wexner Medical CenterJAJohn N. AllanCornell UniversityDJDan JamesPolaris (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kittai et al. (2024) studied this question.

synapsesocial.com/papers/68e6f97db6db64358767447bhttps://doi.org/10.1182/bloodadvances.2023012142
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves2012 · 2,633 citations
  2. 2Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial2021 · 675 citations
  3. 3Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Monotherapy Compared with Combination Therapy for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Systematic Review and Meta-Analysis2023 · 10 citations
  4. 4Acalabrutinib in treatment-naive chronic lymphocytic leukemia2021 · 101 citations